Axsome Therapeutics, Inc. (0HKF.L)
USD 101.16
(-6.16%)
USD 101.16
(-6.16%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 178.07 Million USD | 88.92% |
| 2022 | 94.25 Million USD | 92.01% |
| 2021 | 49.08 Million USD | 0.38% |
| 2020 | 48.9 Million USD | 182.15% |
| 2019 | 17.33 Million USD | 378.88% |
| 2018 | 3.61 Million USD | -45.68% |
| 2017 | 6.66 Million USD | -29.64% |
| 2016 | 9.47 Million USD | 0.0% |
| 2015 | - USD | -100.0% |
| 2014 | 4.44 Million USD | 0.0% |
| 2013 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 179.33 Million USD | 0.36% |
| 2024 Q1 | 178.68 Million USD | 0.35% |
| 2023 Q2 | 184.36 Million USD | 24.89% |
| 2023 Q1 | 147.61 Million USD | 56.61% |
| 2023 FY | 178.07 Million USD | 88.92% |
| 2023 Q4 | 178.07 Million USD | -3.82% |
| 2023 Q3 | 185.13 Million USD | 0.42% |
| 2022 Q2 | 93.45 Million USD | 89.52% |
| 2022 Q4 | 94.25 Million USD | 0.37% |
| 2022 Q1 | 49.31 Million USD | 0.45% |
| 2022 FY | 94.25 Million USD | 92.01% |
| 2022 Q3 | 93.91 Million USD | 0.49% |
| 2021 Q2 | 48.96 Million USD | 0.07% |
| 2021 Q4 | 49.08 Million USD | -0.17% |
| 2021 FY | 49.08 Million USD | 0.38% |
| 2021 Q3 | 49.17 Million USD | 0.43% |
| 2021 Q1 | 48.92 Million USD | 0.05% |
| 2020 FY | 48.9 Million USD | 182.15% |
| 2020 Q1 | 15.54 Million USD | -10.32% |
| 2020 Q2 | 13.74 Million USD | -11.58% |
| 2020 Q3 | 48.02 Million USD | 249.43% |
| 2020 Q4 | 48.9 Million USD | 1.83% |
| 2019 Q3 | 19.1 Million USD | 9.66% |
| 2019 Q1 | 18.81 Million USD | 419.91% |
| 2019 FY | 17.33 Million USD | 378.88% |
| 2019 Q2 | 17.42 Million USD | -7.4% |
| 2019 Q4 | 17.33 Million USD | -9.29% |
| 2018 Q3 | 4.44 Million USD | -14.45% |
| 2018 Q1 | 5.93 Million USD | -10.97% |
| 2018 FY | 3.61 Million USD | -45.68% |
| 2018 Q4 | 3.61 Million USD | -18.49% |
| 2018 Q2 | 5.19 Million USD | -12.5% |
| 2017 Q1 | 8.77 Million USD | -7.34% |
| 2017 FY | 6.66 Million USD | -29.64% |
| 2017 Q4 | 6.66 Million USD | -9.66% |
| 2017 Q3 | 7.37 Million USD | -8.69% |
| 2017 Q2 | 8.07 Million USD | -7.96% |
| 2016 Q1 | - USD | 0.0% |
| 2016 FY | 9.47 Million USD | 0.0% |
| 2016 Q4 | 9.47 Million USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2015 FY | - USD | -100.0% |
| 2015 Q2 | 10.9 Million USD | 0.0% |
| 2015 Q4 | - USD | -100.0% |
| 2015 Q3 | 15.13 Million USD | 38.77% |
| 2015 Q1 | - USD | -100.0% |
| 2014 FY | 4.44 Million USD | 0.0% |
| 2014 Q4 | 4.44 Million USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| uniQure N.V. | 130.06 Million USD | -36.908% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | -212.469% |
| Amicus Therapeutics, Inc. | 387.85 Million USD | 54.089% |
| Atara Biotherapeutics, Inc. | 45.69 Million USD | -289.71% |
| bluebird bio, Inc. | 224.41 Million USD | 20.653% |
| Cara Therapeutics, Inc. | 37.07 Million USD | -380.245% |
| Imunon, Inc. | 1.13 Million USD | -15529.869% |
| Editas Medicine, Inc. | 24.37 Million USD | -630.634% |
| IQVIA Holdings Inc. | 12.95 Billion USD | 98.625% |
| Mettler-Toledo International Inc. | 1.97 Billion USD | 90.986% |
| Myriad Genetics, Inc. | 130.9 Million USD | -36.035% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | 31.061% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | -436.42% |
| Verastem, Inc. | 40.08 Million USD | -344.22% |
| Walgreens Boots Alliance, Inc. | 8.04 Billion USD | 97.786% |
| Waters Corporation | 2.3 Billion USD | 92.276% |
| Thermo Fisher Scientific Inc. | 31.3 Billion USD | 99.431% |
| Biogen Inc. | 7.18 Billion USD | 97.523% |
| Nektar Therapeutics | 112.62 Million USD | -58.109% |
| Perrigo Company plc | 3.63 Billion USD | 95.098% |
| Dynavax Technologies Corporation | 252.41 Million USD | 29.454% |
| Illumina, Inc. | 1.48 Billion USD | 88.041% |
| Corbus Pharmaceuticals Holdings, Inc. | 3.23 Million USD | -5398.311% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -17707.0% |
| Heron Therapeutics, Inc. | 173.75 Million USD | -2.485% |
| Unity Biotechnology, Inc. | 23.53 Million USD | -656.489% |
| BioMarin Pharmaceutical Inc. | 593.09 Million USD | 69.976% |
| Sangamo Therapeutics, Inc. | 33.51 Million USD | -431.314% |
| Evolus, Inc. | 120.35 Million USD | -47.949% |
| Adicet Bio, Inc. | 17.7 Million USD | -905.875% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -5692.778% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 93.412% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | 64.496% |
| FibroGen, Inc. | 89.69 Million USD | -98.524% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 93.489% |
| OPKO Health, Inc. | 222.03 Million USD | 19.801% |
| Homology Medicines, Inc. | 43.17 Million USD | -312.428% |
| Geron Corporation | 35.05 Million USD | -408.031% |
| Alnylam Pharmaceuticals, Inc. | 2.34 Billion USD | 92.4% |
| Exelixis, Inc. | 189.94 Million USD | 6.251% |
| Viking Therapeutics, Inc. | 936 Thousand USD | -18924.573% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 96.74 Million USD | -84.057% |
| Zoetis Inc. | 6.56 Billion USD | 97.287% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -3945.207% |
| Vertex Pharmaceuticals Incorporated | 724.7 Million USD | 75.428% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | -420.825% |
| Ionis Pharmaceuticals, Inc. | 1.4 Billion USD | 87.284% |
| Sarepta Therapeutics, Inc. | 1.13 Billion USD | 84.277% |
| Corcept Therapeutics Incorporated | - USD | -Infinity% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 88.123% |
| Blueprint Medicines Corporation | 610.96 Million USD | 70.854% |
| Insmed Incorporated | 1.19 Billion USD | 85.078% |
| TG Therapeutics, Inc. | 100.11 Million USD | -77.86% |
| Incyte Corporation | 29.16 Million USD | -510.623% |
| Emergent BioSolutions Inc. | 446.5 Million USD | 60.119% |